| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00940121 | Healthy|Pharmacokinetics of Mirabegron | Drug: mirabegron|Drug: mirabegron | Astellas Pharma Inc | Phase 1 | 2009-04-01 | 2013-07-01 |
| NCT00939757 | Healthy|Pharmacokinetics of Mirabegron | Drug: mirabegron | Astellas Pharma Inc | Phase 1 | 2009-05-01 | 2013-06-24 |
| NCT00776516 | Pharmacokinetics of YM178 | Drug: mirabegron|Drug: rifampin | Astellas Pharma Inc | Phase 1 | 2008-10-01 | 2013-07-01 |
| NCT01478568 | Pharmacokinetics of Mirabegron|Healthy Subjects | Drug: mirabegron|Drug: desipramine | Astellas Pharma Inc | Phase 1 | 2008-10-01 | 2014-04-08 |
| NCT01747564 | Healthy Subjects|Plasma Concentration of Mirabegron | Drug: YM178 (mirabegron) | Astellas Pharma Inc | Phase 1 | 2012-08-01 | 2012-12-10 |
| NCT02211846 | Pharmacokinetics of Mirabegron|Neurogenic Detrusor Overactivity|Overactive Bladder | Drug: Mirabegron | Astellas Pharma Inc|Astellas Pharma Europe B.V. | Phase 1 | 2014-07-01 | 2015-10-02 |
| NCT01478529 | Pharmacokinetics of Mirabegron|Bioavailability|Healthy Subjects | Drug: mirabegron OCAS|Drug: mirabegron | Astellas Pharma Inc | Phase 1 | 2006-02-01 | 2013-06-25 |
| NCT02495389 | Overactive Bladder | Drug: mirabegron | Loyola University|Astellas Pharma US, Inc. | Phase 4 | 2015-01-01 | 2017-03-09 |
| NCT02916693 | Erectile Dysfunction|Overactive Bladder|Urinary Incontinence | Drug: Mirabegron | Johns Hopkins University|Astellas Pharma US, Inc. | Phase 1|Phase 2 | 2016-09-01 | 2016-09-23 |
| NCT01285596 | Healthy Volunteers|Pharmacokinetics of Mirabegron | Drug: Mirabegron | Astellas Pharma Inc | Phase 1 | 2009-03-01 | 2013-07-01 |
| NCT02981459 | Urinary Frequency/Urgency|Bladder Irritable|Bladder Pain Syndrome | Drug: Mirabegron | State University of New York at Buffalo|Astellas Pharma Inc | Phase 4 | 2017-01-01 | 2016-12-02 |
| NCT01478490 | Pharmacokinetics of Mirabegron|Healthy Subjects | Drug: mirabegron|Drug: metoprolol | Astellas Pharma Inc | Phase 1 | 2002-09-01 | 2014-04-08 |
| NCT01297192 | Healthy Volunteers|Pharmacokinetics of Mirabegron | Drug: solifenacin succinate|Drug: mirabegron | Astellas Pharma Inc | Phase 1 | 2009-03-01 | 2013-07-25 |
| NCT02044510 | Urinary Bladder, Neurogenic | Drug: Mirabegron|Drug: Placebo | Lawson Health Research Institute | Phase 2|Phase 3 | 2014-07-01 | 2017-03-21 |
| NCT01284868 | Healthy Volunteers|Pharmacodynamics of Mirabegron | Drug: mirabegron|Drug: Bisoprolol|Drug: propranolol|Drug: placebo | Astellas Pharma Inc | Phase 1 | 2009-07-01 | 2013-07-01 |
| NCT02570035 | Overactive Bladder|Cardiovascular Disease | Drug: Mirabegron | Astellas Pharma Inc | | 2012-12-01 | 2015-10-06 |
| NCT02751931 | Neurogenic Detrusor Overactivity | Drug: Mirabegron | Astellas Pharma Europe B.V.|Astellas Pharma Inc | Phase 3 | 2016-06-01 | 2016-12-27 |
| NCT01334905 | Healthy Volunteer|Pharmacokinetics of YM178 | Drug: YM178 | Astellas Pharma Inc|Astellas Pharma Taiwan, Inc. | Phase 1 | 2011-03-01 | 2013-06-10 |
| NCT00965926 | Healthy Volunteer|Pharmacokinetics of YM178 | Drug: YM178 | Astellas Pharma Inc | Phase 1 | 2009-07-01 | 2013-07-15 |
| NCT01964183 | Pharmacokinetics of Mirabegron and Tolterodine|Healthy | Drug: tolterodine|Drug: mirabegron | Astellas Pharma Inc | Phase 4 | 2013-06-01 | 2013-10-15 |
| NCT00912964 | Urinary Bladder, Overactive | Drug: Mirabegron|Drug: Placebo | Astellas Pharma Inc | Phase 3 | 2009-04-01 | 2015-06-05 |
| NCT02536976 | Parkinson Disease|Overactive Bladder|Impaired Cognition | Drug: mirabegron|Drug: Placebo | HealthPartners Institute | Phase 4 | 2015-12-01 | 2016-10-25 |
